CINCINNATI, May 6 /PRNewswire/ --
- Industry Veteran to Lead Global Contract Execution and Negotiation Efforts
Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced the appointment of Patricia Williams to the position of Vice President, Commercial Operations. In this newly created position, Williams will provide leadership for global contract execution and negotiation with the company's biopharmaceutical customers, including master service agreements and changes in scope. Williams will be based in Kendle's European headquarters in Crowthorne, England and will report directly to Chris Bergen, Chief Operating Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
"I am pleased to welcome Patricia to this key leadership role," said Bergen. "As global contracts of US$10 million or more continue to drive double-digit growth within the CRO industry, her expertise will be invaluable in developing and negotiating innovative contract solutions that support both Kendle's profitable growth and meet the changing and long-term needs of our customers."
Williams, who brings a decade of global contract management expertise to this position, joins Kendle from one of the world's largest CROs, serving most recently as Vice President, Global Contracts. Her experience also includes serving as Assistant Global Director, Proposal Development and Contract Management for another global, top-five CRO.
Williams, who earned her Master of Business Administration from Henley Management College (Oxfordshire, England) and her Bachelor of Science from the University of Sussex (Brighton, England), is also a registered nurse. In all, she possesses more than three decades of medical, pharmaceutical and clinical research experience.
About Kendle
Kendle (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202, United States or from the company's Web site at http://www.kendle.com .
Web site: http://www.kendle.com
Patty Frank, Investors, +1-513-763-1992, or Lori Dorer, Media, +1-513-345-1685, both of Kendle. Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO, AP Archive: http://photoarchive.ap.org, PRN Photo Desk, photodesk@prnewswire.com
Comments